Table 1. Descriptive statistics on patient reported outcomes at baseline, demographic and clinical characteristics.
| Overall (N = 109) | Functional Medicine (N = 54) | Standard of Care (N = 55) | |||||
|---|---|---|---|---|---|---|---|
| Factor | N | Statistics | n | Statistics | n | Statistics | p-value |
| Global physical health T-score baseline | 109 | 41.4±7.9 | 54 | 43.2±6.6 | 55 | 39.7±8.7 | 0.022a |
| Global mental health T-score baseline | 109 | 45.6±8.3 | 54 | 45.8±8.4 | 55 | 45.3±8.3 | 0.73a |
| Pain score baseline | 108 | 4.4±2.5 | 54 | 3.5±1.9 | 54 | 5.2±2.7 | <0.001a |
| RAPID3 baseline | 51 | 3.9±2.0 | 6 | 3.2±1.02 | 45 | 4.0±2.1 | 0.36a |
| Age | 109 | 52.9±11.3 | 54 | 51.0±10.6 | 55 | 54.8±11.8 | 0.078a |
| Sex | 109 | 54 | 55 | 0.075c | |||
| male | 35(32.1) | 13(24.1) | 22(40.0) | ||||
| female | 74(67.9) | 41(75.9) | 33(60.0) | ||||
| Smoking | 108 | 53 | 55 | 0.16c | |||
| Never | 62(57.4) | 34(64.2) | 28(50.9) | ||||
| Former or Current | 46(42.6) | 19(35.8) | 27(49.1) | ||||
| CCP | 109 | 54 | 55 | 0.67c | |||
| Positive | 43(39.4) | 23(42.6) | 20(36.4) | ||||
| Negative | 40(36.7) | 20(37.0) | 20(36.4) | ||||
| Unknown | 26(23.9) | 11(20.4) | 15(27.3) | ||||
| RF | 109 | 54 | 55 | 0.12c | |||
| Positive | 37(33.9) | 22(40.7) | 15(27.3) | ||||
| Negative | 50(45.9) | 25(46.3) | 25(45.5) | ||||
| Unknown | 22(20.2) | 7(13.0) | 15(27.3) | ||||
| Treatment at baseline | 108 | 53 | 55 | <0.001C | |||
| Conventional DMARD therapy | 29(26.9) | 12(22.6) | 17(30.9) | ||||
| Biologic DMARD therapy | 66(61.1) | 28(52.8) | 38(69.1) | ||||
| None | 13(12.0) | 13(24.5) | 0(0.0) | ||||
Statistics presented as Mean ± SD or N (column %).
p-values: a = ANOVA, c = Pearson's chi-square test.
CCP = anti-cyclic citrullinated peptide; RF = rheumatoid factor; DMARD = Disease modifying anti-rheumatic drug